ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2020
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 232 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Seroepidemiological, Non-invasive Cohort Study in Tübingen Children Age-stratified by Nursery and School Attendance
A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Reducing Development of Long-term Co-morbidities in Recovered COVID-19 Patients
Who cites it
232 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A systematic review and meta-analysis of the accuracy of SARS-COV-2 IGM and IGG tests in individuals with COVID-19.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Pooled it
- SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature.International journal of environmental research and public health · 2021Pooled it
- Diagnostic performance of COVID-19 serological assays during early infection: A systematic review and meta-analysis of 11 516 samples.Influenza and other respiratory viruses · 2021Pooled it
- Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.Reproductive biomedicine online · 2020Pooled it
- Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents.World journal of pediatrics : WJP · 2024Trial
- Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.Human vaccines & immunotherapeutics · 2022Trial
- SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.Scientific reports · 2022Trial
- Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity.Frontiers in immunology · 2022Trial
- Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity.EBioMedicine · 2020Trial
- Comparative evaluation of four immunoassays for Plasmodium vivax serological detection using recombinant PvMSP1-42 antigen.PLoS neglected tropical diseases · 2026Article
- Four doses of coronavirus disease 2019 vaccination for patients with inborn errors of immunity compared to 3 doses for healthy individuals.The journal of allergy and clinical immunology. Global · 2026Article
- Article
- SARS-CoV-2 and neutralizing antibody dynamics at a remote village in Kenya before widespread COVID-19 vaccine rollout.PLOS global public health · 2026Article
- Preparation of FeMikrochimica acta · 2025Article
- SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults.Nature communications · 2025Article
- Comparative evaluation of in-house ELISA and two commercial serological assays for the detection of antibodies against SARS-CoV-2.Scientific reports · 2025Article
- A high-throughput, fully automated competition assay to evaluate SARS-CoV-2 neutralizing responses and epitope specificity in clinical samples.Scientific reports · 2025Article
- Detection of IgG Antibodies Against COVID-19 N-Protein by Hybrid Graphene-Nanorod Sensor.Biosensors · 2025Article
- Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases.Clinical kidney journal · 2025Article
172 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
BackgroundThe ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making.AimOur objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies.MethodsWe developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.